ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

CPRU Program Gets Basic Concept Approval

October 2, 1987

FDA Moves To Revoke Avastin’s Breast Cancer Accelerated Approval, Genentech Vows To Fight

December 17, 2010

NIAID Advisors Ok Recompetition of Pediatric ACTGs

February 14, 1992

Guest Editorial: Richard Schilsky Reflects On His Past Decade WithThe Board of Scientific Advisors

June 24, 2011

Heart Function Of Breast Cancer Patients Should Be Monitored, Two Studies Find

August 25, 2006

Clearinghouse Opens With Predictable Controversy; Brown Urges ‘Open Minds’

November 12, 1976